Having trouble viewing this email? View in your browser.
ESCMID Logo

20 September 2016
WEEKLY NEWS

Dear colleagues,

Tomorrow global leaders will convene a high-level meeting at the United Nations General Assembly to discuss antimicrobial resistance. You can join the global conversation by using the hashtag #CombatingAMR on @ESCMID’s twitter channel.

Best regards, your ESCMID communications editors

 

ISF/ESCMID Sepsis Award 2017 presented at ECCMID 2017 in Vienna

The ISF Steering Committee will select the top sepsis abstract among all submissions on sepsis-related topics to the 27th ECCMID 2017 for the USD 500 award. The ISF/ESCMID Sepsis Award 2017 will be presented during a symposium jointly organized by ISF and the ECCMID Programme Committee.

› Read more
 

CMI highlight: Risk factors vary in asymptomatic C. difficile colonisation

Researchers in Australia investigated the prevalence and risk factors for asymptomatic toxigenic (TCD) and non-toxigenic C. difficile (NTCD)-colonisation in a broad cross-section of the general hospital population over a three-year period. TCD colonisation was associated with gastro-oesophageal reflux disease, a higher number of admissions in the previous year, and antimicrobial exposure during the current admission, while NTCD colonisation was associated with chronic obstructive pulmonary disease and chronic kidney failure. The researchers conclude that risk factors differ between patients with asymptomatic colonisation by toxigenic and non-toxigenic strains. Given that morbidity is largely driven by toxigenic strains, this novel finding has important implications for disease control and prevention.

› Read more
 

ESCMID/ASM conference on drug development to open in Vienna

The ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance will be held in Vienna, Austria, from 21 – 23 September to help researchers accelerate the development of new antimicrobials for drug-resistant infections. The conference will address issues such as the reliance on very robust preclinical studies, innovative clinical trial design, strong academic-industrial partnerships, and a requirement for early engagement with regulatory bodies in order to facilitate the processes for accelerated antimicrobial development.

› Read more
 

Successful conclusion of ECDC observership programme in Stockholm

The ESCMID observership at the ECDC took place from 5 – 9 September in Stockholm. The 15 ESCMID observers were joined by 10 participants from the European Society for Clinical Virology.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.